Clinical trial · Observational
Ideal Marker for Targeted Axillary Dissection
NCT04580251CI-TRIAL-00069400IMTADcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A multicentre prospective comparative study, comparing the use of various markers (magnetic marker Magseed, iodine seed 125I, carbon suspension) for marking a pathological lymph node in patients with breast carcinoma prior to neoadjuvant therapy and subsequent surgical treatment consisting of targeted axillary dissection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Targeted axillary dissection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Magnetic marker Magseed
- description
- Patients in whom the magnetic marker Magseed is used will be enrolled in this study arm and will undergo targeted axillary dissection.
- interventionNames
- Procedure: Targeted axillary dissection
- label
- Iodine seed 125I marker
- description
- Patients in whom the iodine seed 125I marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
- interventionNames
- Procedure: Targeted axillary dissection
- label
- Carbon suspension
- description
- Patients in whom the carbon suspension marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
- interventionNames
- Procedure: Targeted axillary dissection
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of breast cancer, confirmed with a biopsy * indication of neoadjuvant therapy * biopsy of pathologically enlarged axillary lymph node and marking of the lymph node using one of the markers before neoadjuvant chemotherapy * surgical treatment after neoadjuvant chemotherapy (targeted axillary dissection) Exclusion Criteria: * refusal to participate in the study * another treatment protocol, which does not include targeted axillary dissection
References
Publications (1)
- DERIVEDZatecky J, Coufal O, Zapletal O, Kubala O, Kepicova M, Faridova A, Raus K, Gatek J, Kosac P, Peteja M. Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial. World J Surg Oncol. 2023 Aug 19;21(1):252. doi: 10.1186/s12957-023-03147-x. PMID 37596658